Ligand Pharmaceuticals (LGND) Change in Receivables (2010 - 2026)

Ligand Pharmaceuticals has disclosed Change in Receivables across 17 years of filings, most recently posting -$6.4 million for Q1 2026.

• Change in Receivables for Q1 2026 came in at -$6.4 million, down 1212.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.8 million (up 40.54% YoY), and the FY2025 annual result was $21.7 million, up 236.54% from the prior year.
• Change in Receivables came in at -$6.4 million for Q1 2026 at Ligand Pharmaceuticals, down from $2.1 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $20.4 million in Q2 2022 to a low of -$43.6 million in Q1 2022.
• The 5-year median for Change in Receivables is $576000.0 (2025), against an average of -$1.8 million.
• Across the five-year window, Change in Receivables plunged 1709.95% in 2022 and soared 757.15% in 2024, its largest moves.
• Ligand Pharmaceuticals' Change in Receivables stood at -$34.8 million in 2022, then jumped by 91.85% to -$2.8 million in 2023, then jumped by 299.82% to $5.7 million in 2024, then tumbled by 63.16% to $2.1 million in 2025, then plunged by 407.09% to -$6.4 million in 2026.
• The last three Change in Receivables figures came in at -$6.4 million (Q1 2026), $2.1 million (Q4 2025), and $16.3 million (Q3 2025), per Business Quant data.